Study leverages deep learning-enabled analysis of the
aggregation of real-world multimodal data to validate predictive
signatures associated with response to immunotherapy and prognosis
of patients with stage IV non-small cell lung cancer
Since study launch, 12 sites across 5 countries have already
signed up for participation
BOSTON
and LAUSANNE, Switzerland, Jan.
11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH),
the creator of a global data pooling and knowledge sharing platform
that advances data-driven medicine, announced today strong traction
in the launch phase of their DEEP-Lung-IV clinical study
(NCT04994795). Since officially launching last month, 12 sites
across 5 countries have already signed up for participation in the
study.
![SOPHiA GENETICS Logo SOPHiA GENETICS Logo](https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg)
Despite the clinical promise of immunotherapy, significant
challenges remain as the majority of non-small cell lung cancer
(NSCLC) patients fail to respond to immune checkpoint inhibitors.
Today, PD-L1 is the only standard predictive biomarker for immune
checkpoint inhibitor efficacy, however it remains a very suboptimal
biomarker with several well-characterized issues limiting its
clinical utility. Thus, there is an urgent need to discover new
predictive biomarkers of response to immunotherapy. SOPHiA
GENETICS' DEEP-Lung-IV clinical study leverages deep
learning-enabled analysis of the aggregation of real-world
multimodal data (including genomics, radiomics and clinical data)
to identify and validate predictive signatures associated with
response to immunotherapy and prognosis of patients with metastatic
(stage IV) NSCLC. Such signatures could help identify patients that
are likely to benefit from immunotherapy versus those that are not,
as well as stratify patients according to risk, helping clinicians
make more informed therapeutic decisions for their patients and
supporting biopharma to ensure the right patients are selected for
clinical trials.
The 12 initial sites that have signed up for participation in
the study include Carbone Comprehensive Cancer Center at
University of Wisconsin and Holden
Comprehensive Cancer Center at University of
Iowa Health Care in the US, Assistance Publique-Hôpitaux de
Paris and Hospices Civils de
Lyon in France, Leipzig University in Germany, Sunnybrook Health Sciences Center in
Toronto, Canada, and Shaare Zedek
Medical Center in Jerusalem,
Israel, among others. Together, these sites are projected to
contribute over 2,000 of the 4,000 total patients targeted for
enrollment over the course of the study. An additional 10 sites are
lined up for onboarding in the first quarter of 2022, with more
expected candidates to follow.
"We are very pleased with the strong traction since launching
our DEEP-Lung-IV multimodal clinical study. The positive reception
from the participating sites highlights the high interest in
unlocking the predictive potential of multimodal health data sets
through large-scale real-world studies" said Dr. Jurgi Camblong,
Co-founder and Chief Executive Officer at SOPHiA GENETICS. "We very
much look forward to further accelerating this momentum in the
first months of 2022."
To learn more about the DEEP-Lung-IV clinical study, visit
https://clinicaltrials.gov/ct2/show/NCT04994795.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg